Cancers (Dec 2021)

Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)

  • Anne-Sophie Belmont,
  • Christophe Sajous,
  • Amandine Bruyas,
  • Sara Calattini,
  • Stéphanie Cartalat,
  • Marion Chauvenet,
  • Marc Colombel,
  • Stéphane Dalle,
  • Tristan Dagonneau,
  • Marie Darrason,
  • Gilles Devouassoux,
  • Michaël Duruisseaux,
  • Marielle Guillet,
  • Olivier Glehen,
  • Pierre Philouze,
  • François Tronc,
  • Thomas Walter,
  • Benoît You,
  • Gilles Freyer

DOI
https://doi.org/10.3390/cancers14010029
Journal volume & issue
Vol. 14, no. 1
p. 29

Abstract

Read online

This article presents the protective measures put in place at the “Institut de Cancérologie des Hospices de Lyon” (IC-HCL) during the first wave of the COVID-19 pandemic in France (spring 2020) and how they impacted IC-HCL clinical activity. Spring 2020 activities were compared to winter 2019–2020. Results showed a decrease of activity of 9% for treatment dispensations, 17% for multidisciplinary team meetings, 20% for head and neck and thoracic surgeries, and 58% for new patient enrolment in clinical trials. Characteristics of patients treated for solid cancer and hospitalized for COVID-19 during spring 2020 were collected in a retrospective study. Mortality was attributed to COVID-19 for half of the cases, 82% being patients above 70 and 73% being stage IV. This is in concordance with current findings concluding that the risk of developing severe or critical symptoms of COVID-19 is correlated with factors co-occurring in cancer patients and not to the cancer condition per se. While a number of routines and treatment regimens were changed, there was no major decline in numbers of treatments conducted at the IC-HCL during the first wave of the COVID-19 pandemic that hit France between March and May 2020, except for clinical trials and some surgery activities.

Keywords